Gilead Sciences ((GILD)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Gilead Sciences is currently recruiting participants for a clinical study titled ‘An Umbrella Phase 1b, Open-label, Multi-Cohort Study to Evaluate Safety, Pharmacokinetics, and Antiviral Activity of Novel Antiretrovirals in Participants With HIV-1 Substudy-05: GS-3242’. The study aims to assess the safety and effectiveness of novel antiretrovirals, specifically GS-3242, in individuals living with HIV-1. This research is significant as it explores new treatment options for managing HIV-1 infection.
The intervention being tested is GS-3242, an experimental drug administered orally. Participants will receive a single dose of GS-3242, followed by a regimen of either Biktarvy® or an alternative standard of care antiretroviral therapy.
The study is designed as an interventional trial with a sequential intervention model, focusing on treatment as its primary purpose. There is no masking involved, meaning all participants and researchers know the treatment being administered.
The study began on May 23, 2025, with the latest update submitted on August 20, 2025. These dates are crucial as they indicate the study’s progress and the timeline for potential results.
The update on this study could impact Gilead Sciences’ stock performance positively, as successful results may enhance their portfolio of HIV treatments. This could also influence investor sentiment, particularly in the competitive landscape of HIV treatment development.
The study is ongoing, and further details are available on the ClinicalTrials portal.